Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $5.92 Average Target Price from Brokerages

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has received an average rating of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $5.92.

A number of analysts have issued reports on the company. Craig Hallum lifted their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research note on Friday, March 7th. Piper Sandler reissued a “neutral” rating and set a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Leerink Partners boosted their target price on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research report on Friday, March 7th. Jefferies Financial Group reissued a “buy” rating and set a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th.

Hedge Funds Weigh In On Xeris Biopharma

Large investors have recently bought and sold shares of the business. NewEdge Advisors LLC purchased a new position in Xeris Biopharma during the 4th quarter valued at $34,000. R Squared Ltd purchased a new position in Xeris Biopharma during the 4th quarter valued at $42,000. Wealth Enhancement Advisory Services LLC purchased a new position in Xeris Biopharma during the 3rd quarter valued at $35,000. Cibc World Markets Corp purchased a new position in Xeris Biopharma during the 4th quarter valued at $44,000. Finally, Raymond James Financial Inc. purchased a new position in Xeris Biopharma during the 4th quarter valued at $45,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Price Performance

NASDAQ:XERS opened at $4.82 on Monday. Xeris Biopharma has a 1 year low of $1.69 and a 1 year high of $4.90. The stock’s 50 day simple moving average is $3.68 and its two-hundred day simple moving average is $3.32. The company has a market cap of $741.99 million, a price-to-earnings ratio of -10.71 and a beta of 2.32.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.